NCT00418717View on ClinicalTrials.gov

Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

etanercept

Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)

Trial Locations (12)

037-0053

Nunoya-cho Goshogawara

839-0863

Kokubu, Kurume

370-0004

Inomachi Takasaki

666-0195

Higashiuneno Kawanishi

663-8501

Mukogawa-cho, Nishinomiya

305-0854

Kamiyokoba, Tsukuba

513-0824

Douhaku, Suzuka

517-0214

Hazama, Isobe-cho, Shima

514-1101

Hisai Myojin-cho, Tsu

857-1195

Yamato, Sasebo

712-8044

Higashizuka, Kurashiki

105-0001

Toranomon, Minato-ku

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00418717 - Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA | Biotech Hunter | Biotech Hunter